Before it was molecularly cloned in 1994, acute-phase response factor or signal transducer
and activator of transcription (STAT) 3 was the focus of intense research into understanding …

Castleman disease (CD), a heterogeneous group of disorders that share morphological
features, is divided into unicentric CD and multicentric CD (MCD) according to the clinical …

Over the past decades, survival of patients with acute lymphoblastic leukemia (ALL) has
dramatically improved, but the subgroup of patients with relapsed/refractory ALL still …

Amyloid A amyloidosis is thought to be the second most common form of systemic
amyloidosis behind amyloidosis secondary to monoclonal Ig. It is the result of deposition of …

Abstract Coronavirus disease 2019 (COVID-19) outbreak has become a global public health
emergency and has led to devastating results. Mounting evidence proposes that the disease …

Innate and adaptive immune responses have a well-known link and represent the distinctive
origins of several diseases, many of which may be the consequence of the loss of balance …

Abstract Interleukin-6 (IL-6) signaling is a critical target in inflammatory pathways. Today,
tocilizumab (TCZ) and sarilumab (SAR), two IL-6 receptor-inhibiting monoclonal antibodies …

Background Siltuximab is recommended by international consensus as a first-line treatment
for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety …

Idiopathic multicentric Castleman disease (iMCD) is a rare heterogeneous disorder
involving multicentric lymphadenopathy, systemic inflammation, and cytokine-driven organ …

Castleman disease (CD) describes a group of rare hematologic conditions involving
lymphadenopathy with characteristic histopathology and a spectrum of clinical …